Cardiac Inflammation in Diabetes: A Narrative Review of the Metabolic Immune Myocardial Injury Cycle Cardiac Inflammation in Diabetes
Article metrics
OJS usage and citation sourcesViews and downloads are recorded by OJS; statistics processing may be delayed. A dash means the source count is unavailable. Search Google Scholar
Main Article Content
Abstract
Diabetes mellitus is a major metabolic disorder associated with progressive cardiovascular complications, including diabetic cardiomyopathy. Increasing evidence indicates that cardiac inflammation links metabolic stress to myocardial injury and structural remodeling. However, the temporal and causal relationships among these processes, particularly the potential feedback from myocardial injury to metabolic stress, remain incompletely established. Objective: This review synthesizes current evidence on the mechanisms underlying cardiac inflammation in diabetes and proposes an integrated framework linking metabolic, immune, and myocardial respones. Methods: A structured narrative review was conducted with reference to the principles of the Scale for the Assessment of Narrative Review Articles (SANRA). Literature published from January 2020 to July 2026 was identified through PubMed, Scopus, Web of Science, and ScienceDirect using combinations of MeSH and free-text terms related to diabetes, diabetic cardiomyopathy, inflammation, oxidative stress, mitochondrial dysfunction, NLRP3 inflamasome, and pyroptosis. Results: Chronic hyperglycemia and lipotoxicity promote advanced glycation end products, oxidative stress, and mitochondrial dysfunction, which activate RAGE, TLR4, NF-κB, and NLRP3 inflamasome signaling. These pathways promote inflammatory communication among macrophages, cardiomyocytes, and fibroblasts, contributing to pyroptosis, hypertrophy, fibrosis, and myocardial dysfunction. Persistent tissue injury may further amplify local inflammation through damage-associated molecular patterns and mitochondrial danger signals. However, evidence supporting a complete closed positive feedback loop, particularly a causal pathway from myocardial injury back to the initiating metabolic stress, remains limited. Conclusion: The metabolic–immune–myocardial injury cycle is proposed as a conceptual hypothesis to explain the persistence and potential amplification of cardiac inflammation in diabetes. Targeting this interconnected network may provide opportunities for preventing or slowing diabetic cardiomyopathy progression.
Article Details
Section

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
[1] Ritchie RH, Abel ED. Basic Mechanisms of Diabetic Heart Disease. Circ Res 2020;126:1501–25. https://doi.org/10.1161/CIRCRESAHA.120.315913.
[2] Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol 2020;17:585–607. https://doi.org/10.1038/s41569-020-0339-2.
[3] Pan KL, Hsu YC, Chang ST, Chung CM, Lin CL. The Role of Cardiac Fibrosis in Diabetic Cardiomyopathy: From Pathophysiology to Clinical Diagnostic Tools. Int J Mol Sci 2023;24. https://doi.org/10.3390/ijms24108604.
[4] Ramesh P, Yeo JL, Brady EM, McCann GP. Role of inflammation in diabetic cardiomyopathy. Ther Adv Endocrinol Metab 2022;13. https://doi.org/10.1177/20420188221083530.
[5] Peng ML, Fu Y, Wu CW, Zhang Y, Ren H, Zhou SS. Signaling Pathways Related to Oxidative Stress in Diabetic Cardiomyopathy. Front Endocrinol (Lausanne) 2022;13. https://doi.org/10.3389/fendo.2022.907757.
[6] Song M, Dai H, Zhou Q, Meng X. The immunology of diabetic cardiomyopathy. Front Endocrinol (Lausanne) 2025;16. https://doi.org/10.3389/fendo.2025.1542208.
[7] De Blasio MJ, Ritchie RH. Inflammatory signalling in diabetic cardiomyopathy: molecular mechanisms and potential therapeutic strategies. Nat Rev Cardiol 2026. https://doi.org/10.1038/s41569-026-01274-y.
[8] Huo S, Wang M, Du M, Ren B, Yang T, Peng L, et al. Macrophage-derived S100A9 promotes diabetic cardiomyopathy by disturbing mitochondrial quality control via STAT3 activation. Int J Biol Sci 2025;21:3061–80. https://doi.org/10.7150/ijbs.111128.
[9] De Geest B, Mishra M. Role of Oxidative Stress in Diabetic Cardiomyopathy. Antioxidants 2022;11. https://doi.org/10.3390/antiox11040784.
[10] Peng ML, Fu Y, Wu CW, Zhang Y, Ren H, Zhou SS. Signaling Pathways Related to Oxidative Stress in Diabetic Cardiomyopathy. Front Endocrinol (Lausanne) 2022;13. https://doi.org/10.3389/fendo.2022.907757.
[11] Wang Y, Luo W, Han J, Khan ZA, Fang Q, Jin Y, et al. MD2 activation by direct AGE interaction drives inflammatory diabetic cardiomyopathy. Nature Communications 2020;11. https://doi.org/10.1038/s41467-020-15978-3.
[12] Chen X, Qian J, Liang S, Qian J, Luo W, Shi Y, et al. Hyperglycemia activates FGFR1 via TLR4/c-Src pathway to induce inflammatory cardiomyopathy in diabetes. Acta Pharm Sin B 2024;14:1693–710. https://doi.org/10.1016/j.apsb.2024.01.013.
[13] Zhang S, Zhu X, Chen Y, Wen Z, Shi P, Ni Q. The role and therapeutic potential of macrophages in the pathogenesis of diabetic cardiomyopathy. Front Immunol 2024;15. https://doi.org/10.3389/fimmu.2024.1393392.
[14] Nakamura M. Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy. Journal of Pharmacy and Pharmaceutical Sciences 2024;27. https://doi.org/10.3389/jpps.2024.12568.
[15] Zhan J, Jin K, Xie R, Fan J, Tang Y, Chen C, et al. AGO2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation. Circulation 2024;149:1102–20. https://doi.org/10.1161/CIRCULATIONAHA.123.065546.
[16] Hao J, Zhou J, Hu S, Zhang P, Wu H, Yang J, et al. RTA 408 ameliorates diabetic cardiomyopathy by activating Nrf2 to regulate mitochondrial fission and fusion and inhibiting NF-jB-mediated inflammation. Am J Physiol Cell Physiol 2024;326:C331–47. https://doi.org/10.1152/ajpcell.00467.2023.
[17] Rostami A, Palomer X, Pizarro-Delgado J, Barroso E, Valenzuela-Alcaraz B, Crispi F, et al. PPARβ/δ prevents inflammation and fibrosis during diabetic cardiomyopathy. Pharmacol Res 2024;210. https://doi.org/10.1016/j.phrs.2024.107515.
[18] Cohen CD, De Blasio MJ, Farrugia GE, Dona MSI, Hsu I, Prakoso D, et al. Mapping the cellular and molecular landscape of cardiac non-myocytes in murine diabetic cardiomyopathy. IScience 2023;26. https://doi.org/10.1016/j.isci.2023.107759.
[19] Sun Y, Ding S. Nlrp3 inflamasome in diabetic cardiomyopathy and exercise intervention. Int J Mol Sci 2021;22. https://doi.org/10.3390/ijms222413228.
[20] Ding P, Song Y, Yang Y, Zeng C. NLRP3 inflamasome and pyroptosis in cardiovascular diseases and exercise intervention. Front Pharmacol 2024;15. https://doi.org/10.3389/fphar.2024.1368835.
[21] Huang Y, Xu W, Zhou R. NLRP3 inflamasome activation and cell death. Cell Mol Immunol 2021;18:2114–27. https://doi.org/10.1038/s41423-021-00740-6.
[22] Seoane PI, Lee B, Hoyle C, Yu S, Lopez-Castejon G, Lowe M, et al. The NLRP3–inflamasome as a sensor of organelle dysfunction. Journal of Cell Biology 2020;219. https://doi.org/10.1083/JCB.202006194.
[23] Zeng C, Duan F, Hu J, Luo B, Huang B, Lou X, et al. NLRP3 inflamasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. Redox Biol 2020;34. https://doi.org/10.1016/j.redox.2020.101523.
[24] Zhang T, Ding S, Wang R. Research progress of mitochondrial mechanism in NLRP3 inflamasome activation and exercise regulation of NLRP3 inflamasome. Int J Mol Sci 2021;22. https://doi.org/10.3390/ijms221910866.
[25] Yan M, Li L, Wang Q, Shao X, Luo Q, Liu S, et al. The Chinese herbal medicine Fufang Zhenzhu Tiaozhi protects against diabetic cardiomyopathy by alleviating cardiac lipotoxicity-induced oxidative stress and NLRP3-dependent inflamasome activation. Biomedicine and Pharmacotherapy 2022;148. https://doi.org/10.1016/j.biopha.2022.112709.
[26] Li Y, Luo M, Chang Q, Cao S, Wang Y, Chen Z, et al. High-intensity interval training and moderate-intensity continuous training alleviate vascular dysfunction in spontaneously hypertensive rats through the inhibition of pyroptosis. Heliyon 2024;10. https://doi.org/10.1016/j.heliyon.2024.e39505.
[27] Wang J, Li Y, Li L, Liang H, Ye H, Kang P, et al. Effect of NLRP3 gene knockdown on pyroptosis and ferroptosis in diabetic cardiomyopathy injury. BMC Cardiovasc Disord 2024;24. https://doi.org/10.1186/s12872-024-04010-x.
[28] Li T, Wang P, Wang X, Liu Z, Zhang Z, Zhang Y, et al. Inflammation and Insulin Resistance in Diabetic Chronic Coronary Syndrome Patients. Nutrients 2023;15. https://doi.org/10.3390/nu15122808.
[29] Kufazvinei TTJ, Chai J, Boden KA, Channon KM, Choudhury RP. Emerging opportunities to target inflammation: myocardial infarction and type 2 diabetes. Cardiovasc Res 2024;120:1241–52. https://doi.org/10.1093/cvr/cvae142.
[30] Nan W, Yin J, Hao W, Meng H, Wu J, Yin X, et al. Cardamonin protects against diabetic cardiomyopathy by activating macrophage NRF2 signaling through molecular interaction with KEAP1. Food Funct 2024;15:11083–95. https://doi.org/10.1039/d4fo03543g.
[31] Wen X, Fan J, Duan X, Zhu X, Bai J, Zhang T. Mitochondrial DNA in Exercise-Mediated Innate Immune Respones. Int J Mol Sci 2025;26. https://doi.org/10.3390/ijms26073069.
[32] Li S, Zhang J, Zhao Y, Kang L, Jie H, Dong B. (Pro)renin receptor aggravates myocardial pyroptosis in diabetic cardiomyopathy through AMPK-NLRP3 pathway. Front Pharmacol 2024;15. https://doi.org/10.3389/fphar.2024.1453647.
[33] Meier DT, de Paula Souza J, Donath MY. Targeting the NLRP3 inflamasome–IL-1β pathway in type 2 diabetes and obesity. Diabetologia 2025;68:3–16. https://doi.org/10.1007/s00125-024-06306-1.
[34] Tan Y, Chen S, Gao T, Wang S, Zhou X, Liu M. Exploring the role of NLRP3 infalmmasome in diabetes: a literature review and bibliometric analysis. Front Endocrinol (Lausanne) 2024;15. https://doi.org/10.3389/fendo.2024.1443798.
[35] Cabral JE, Wu A, Zhou H, Pham MA, Lin S, McNulty R. Targeting the NLRP3 inflamasome for inflammatory disease therapy. Trends Pharmacol Sci 2025;46:503–19. https://doi.org/10.1016/j.tips.2025.04.007.
[36] Chen Y, Ye X, Escames G, Lei W, Zhang X, Li M, et al. The NLRP3 inflamasome: contributions to





